| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | ABIOMED INC | 1,450,000 | 163,386,000 | 37.26% | ||
| 2 | REVANCE THERAPEUTICS INC COM | 4,592,047 | 95,055,000 | 21.68% | ||
| 3 | ENTELLUS MEDICAL INC | 3,813,197 | 72,336,000 | 16.50% | ||
| 4 | AXOGEN INC | 4,861,111 | 43,750,000 | 9.98% | ||
| 5 | CORIUM INTERNATIONAL INC | 9,353,304 | 37,974,000 | 8.66% | ||
| 6 | ENDOLOGIX INC | 1,257,468 | 14,217,000 | 3.24% | ||
| 7 | MEDICINOVA INC COM NEW | 1,170,370 | 7,057,000 | 1.61% | ||
| 8 | LIGAND PHARMACEUTICALS INC | 32,893 | 2,420,000 | 0.55% | ||
| 9 | ACURA PHARMACEUTICALS INC | 1,956,397 | 1,506,000 | 0.34% | ||
| 10 | Catalyst Biosciences | 1,179,352 | 778,000 | 0.18% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001398344-17-003079, filed 2017.03.07).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
